References
- Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, et al. NCCN guidelines insights: head and neck cancers, Version 1.2018. J Natl Compr Canc Netw 2018; 16: 479-90. doi: 10.6004/jnccn.2018.0026
- Hong RL, Hsiao CF, Ting LL, Ko JY, Wang CW, Chang JTC, et al. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Ann Oncol 2018; 29: 1972-79. doi: 10.1093/annonc/mdy249
- Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 2016; 17: 1509-20. doi: 10.1016/S1470-2045(16)30410-7
- Au KH, Ngan RKC, Ng AWY, Poon DMC, Ng WT, Yuen KT, et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: a report of 3328 patients (HKNPCSG 1301 study). Oral Oncol 2018; 77: 16-21. doi: 10.1016/j.oralon-cology.2017.12.004
- Ma BBY, King A, Lo YMD, Yau YY, Zee B, Hui EP, et al. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 714-20. doi: 10.1016/j.ijrobp.2006.05.064
- Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350: 2461-70. doi:10.1056/NEJMoa032260
- Leung SF, Chan KC, Ma BB, Hui EP, Mo F, Chow KC, et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 2014; 25: 1204-8. doi: 10.1093/annonc/mdu117
- Leung SF, Chan AT, Zee B, Ma B, Chan LY, Johnson PJ, et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 2003; 98: 288-91. doi: 10.1002/cncr.114969
- Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006; 24: 5414-18. doi: 10.1200/JCO.2006.07.7982
- Tang LQ, Chen QY, Fan W, Liu H, Zhang L, Guo L, et al. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol 2013; 31: 2861-69. doi: 10.1200/JCO.2012.46.0816
- Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365: 2041-54. doi: 10.1016/S0140-6736(05)66698-6
- Li H, Cao D, Li S, Chen B, Zhang Y, Zhu Y, et al. Synergistic association of hepatitis B surface antigen and plasma Epstein-Barr virus DNA load on distant metastasis in patients with nasopharyngeal carcinoma. JAMA Netw Open 2023; 6: e2253832. doi: 10.1001/jamanetworkopen.2022.53832
- Xu T, Huang Z, Deng Y, Wang S, Su B, Wei W, et al. Clinical implications of hepatitis B viral infection in Epstein-Barr virus-associated nasopharyngeal carcinoma. J Clin Virol 2015; 64: 64-71. doi: 10.1016/j.jcv.2014.11.024
- Liu X, Li X, Jiang N, Lei Y, Tang LL, Chen L, et al. Prognostic value of chronic hepatitis B virus infection in patients with nasopharyngeal carcinoma: analysis of 1301 patients from an endemic area in China. Cancer 2014; 120: 68-76. doi: 10.1002/cncr.28377
- Weng JJ, Wei JZ, Li M, Lu JL, Qin YD, et al. Effects of hepatitis B virus infection and antiviral therapy on the clinical prognosis of nasopharyngeal carcinoma. Cancer Med 2020; 9: 541-51. doi: 10.1002/cam4.2715
- Liu T, Liu LT, Lin JY, Shen BW, Guo SS, Liu SL, et al. Management of suboptimal response to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: re-induction therapy or direct to Radiotherapy? Radiother Oncol 2021; 163: 185-91. doi: 10.1016/j.radonc.2021.08.010
- NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers (Version 5.2025). [internet]. [cited 2025 May 15]. Available at: http://www.nccn.org
- Li H, Chen M, Li S, Luo C, Qiu X, Ruan G, Mao Y, et al. Survival impact of additional induction chemotherapy in nasopharyngeal carcinoma with chronic hepatitis B infection: a retrospective, bi-center study. Ann Transl Med 2022; 10: 731. doi: 10.21037/atm-22-33
- Zhang LL, Zhou GQ, Li YC, Lin AH, Ma J, Qi ZY, et al. Induction chemotherapy has no prognostic value in patients with locoregionally advanced nasopharyngeal carcinoma and chronic hepatitis B infection in the IMRT era. Transl Oncol 2017; 10: 800-5. doi: 10.1016/j.tranon.2017.07.001
- Ferrari C. HBV and the immune response. Liver Int 2015; 35 (Suppl 1): 121-28. doi: 10.1111/liv.12749
- Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol 2016; 64 (1 Suppl): S84-101. doi: 10.1016/j. jhep.2016.02.021
- Lv JW, Chen YP, Huang XD, Zhou GQ, Chen L, Li WF, Tang LL, et al. Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: a large-scale, big-data intelligence platform-based analysis from an endemic area. Cancer 2017; 123: 3540-49. doi: 10.1002/cncr.30775
- Sweiss K, Lee J, Mahmud N, Calip GS, Park Y, et al. Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant. Bone Marrow Transplant 2020; 55: 199-206. doi: 10.1038/s41409-019-0681-3
- Jia T, Zhang R, Zhu HY, Liang JH, Wang L, Wu W, et al. Prognostic significance of peripheral blood absolute monocyte count and lymphocyte to monocyte ratio in anaplastic large cell lymphoma. Cancer Biomark 2018; 22: 807-13. doi: 10.3233/CBM-181505
- Xie X, Gong S, Jin H, Yang P, Xu T, et al. Radiation-induced lymphopenia correlates with survival in nasopharyngeal carcinoma: impact of treatment modality and the baseline lymphocyte count. Radiat Oncol 2020; 15: 65. doi: 10.1186/s13014-020-01494-7
- Cho O, Oh YT, Chun M, Noh OK, Hoe JS, Kim H. Minimum absolute lymphocyte count during radiotherapy as a new prognostic factor for nasopharyngeal cancer. Head Neck 2016; 38 (Suppl 1): E1061-7. doi: 10.1002/hed.24158
- Price JM, Mistry HB, Betts G, Cheadle EJ, Dixon L, Garcez K, et al. Pretreatment lymphocyte count predicts benefit from concurrent chemotherapy with radiotherapy in oropharyngeal cancer. J Clin Oncol 2022; 40: 2203-12. doi: 10.1200/JCO.21.01991
- Wu YL, Yang KB, Huang Y, Shi JR, He QS, Chen L, et al. Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study. Radiat Oncol 2022; 17: 138. doi: doi: 10.1186/s13014-022-02095-2
- Buzby GP, Mullen JL, Matthews DC, Hobbs CL, Rosato EF, et al. Prognostic nutritional index in gastrointestinal surgery. Am J Surg 1980; 139: 160-7. doi: 10.1016/0002-9610(80)90246-9
- Ye YF, Xiang YQ, Fang F, Gao R, Zhang LF, Xie SH, et al. Hepatitis B virus infection and risk of nasopharyngeal carcinoma in southern China. Cancer Epidemiol Biomarkers Prev 2015; 24: 1766-73. doi: 10.1158/1055-9965. EPI-15-0344
- You J, Sriplung H, Geater A, Chongsuvivatwong V, Zhuang L, Chen HY, et al. Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B. World J Gastroenterol 2008; 14: 1112-9. doi: 10.3748/wjg.14.1112
- Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial. J Clin Oncol 2022; 40: 2420-5. doi: 10.1200/JCO.22.00327
- Bongiovanni A, Vagheggini A, Fausti V, Mercatali L, Calpona S, Di Menna G, et al. Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: an updated network meta-analysis. Crit Rev Oncol Hematol 2021; 160: 103244. doi: 10.1016/j.critrevonc.2021.103244